Le Lézard
Classified in: Health, Science and technology

Global Encephalitis Vaccines Market (2020 to 2025) - Growth, Trends, and Forecast - ResearchAndMarkets.com

The "Encephalitis Vaccines Market - Growth, Trends, and Forecast (2020 - 2025)" report has been added to ResearchAndMarkets.com's offering.

The Encephalitis Vaccines market is projected to grow with a CAGR of 5.2% over the forecast period. The major factor attributing to the growth of the market is the high mortality and morbidity rate caused due to the incidence of encephalitis virus. Furthermore, increasing government initiatives for vaccination programs is boosting the market.

Companies Mentioned

Key Market Trends

Japanese Encephalitis Segment is Dominating the Encephalitis Vaccines Market

The Japanese encephalitis vaccine segment is estimated to grow at a significant rate over the forecast period. According to WHO, the estimated annual number of clinical cases of JE are about 68000 globally every year. Furthermore, the government initiatives for the JE vaccination programs is further boosting the segment. Governments of China and India came up with national immunization plans that carry out mass vaccinations. In 2014, vaccination against Japanese encephalitis was added to India's Universal Immunization Programme, which resulted in a significant procurement of vaccination doses since then. Such initiatives are gaining pervasiveness in other Asian countries such as Thailand, Malaysia, and the Philippines. The marketing is witnessing strong demand for JE vaccines due to routine immunization. Therefore, the inclusion of vaccination against Japanese encephalitis in national immunization plans will act as one of the significant growth drivers for the Japanese encephalitis vaccine segment during the forecast period.

Asia-Pacific Grows With Highest CAGR and Expected to do Same in the Forecast Period

The market in Asia will grow exponentially over the forecast period. Japanese encephalitis is endemic mostly in Asian countries. There is no cure for the disease. Therefore, organizations such as UNICEF, WHO, and Gavi are focusing on preventing the disease from spreading through vaccination. To ensure maximum immunization, the JE vaccines has been made mandatory for newborn children. This will provide incredible opportunities for the manufacturers catering to the region. Furthermore, growing investment in the R&D sector, entry of new vaccine manufacturers in countries like India and China, increase number of travelers in the region, medical tourism is propelling the market growth in the region.

Reasons to Purchase this report:

Key Topics Covered:


1.1 Study Deliverables

1.2 Study Assumptions

1.3 Scope of the Study




4.1 Market Overview

4.2 Market Drivers

4.2.1 High Mortality and Morbidity Rate Caused Due to the Incidence of Encephalitis Virus

4.2.2 Rise in Government Initiatives for Vaccination Programs

4.3 Market Restraints

4.3.1 Side Effects and Challenges With the Vaccines

4.4 Porter's Five Force Analysis

4.4.1 Threat of New Entrants

4.4.2 Bargaining Power of Buyers/Consumers

4.4.3 Bargaining Power of Suppliers

4.4.4 Threat of Substitute Products

4.4.5 Intensity of Competitive Rivalry


5.1 By Vaccine Type

5.1.1 Mouse Brain-Derived, Inactivated Vaccine

5.1.2 Cell Culture-Derived, Inactivated Vaccine

5.1.3 Cell Culture-Derived, Live Attenuated Vaccine

5.2 By Type Of Indication

5.2.1 Japanese Encephalitis

5.2.2 Tick-Borne Encephalitis

5.2.3 Rabies Encephalitis

5.3 By End-User

5.3.1 Child

5.3.2 Adult

5.4 Geography

5.4.1 North America United States Canada Mexico

5.4.2 Europe Germany United Kingdom France Italy Spain Rest of Europe

5.4.3 Asia-Pacific China Japan India Australia South Korea Rest of Asia-Pacific

5.4.4 Middle-East and Africa GCC South Africa Rest of Middle-East and Africa

5.4.5 South America Brazil Argentina Rest of South America


6.1 Company Profiles


For more information about this report visit https://www.researchandmarkets.com/r/vtinkk

These press releases may also interest you

at 03:42
Vico Therapeutics, a Leiden, the Netherlands, based biotech company focusing on the development of RNA modulating therapies for rare neurological disorders, today announced the appointment of Rupert Sandbrink, M.D., Ph.D., as the company's chief...

at 03:35
Technavio has been monitoring the enzyme-linked immunosorbent assay (Elisa) market and it is poised to grow by USD 124.55 mn during 2020-2024, progressing at a CAGR of about 5% during the forecast period. The report offers an up-to-date analysis...

at 03:10
"Mild cognitive impairment" (MCI) is the new frontline in the battle against Alzheimer's disease (AD), says Leslie Norins, M.D., Ph.D. CEO of MCI911.com, a new information service and clearinghouse. He advises, "Start counterattacking immediately...

at 03:05
WISE Srl, a medical device company developing next-generation implantable leads for neuromonitoring, neuromodulation and brain-machine interfacing, today announced the closing of a EUR 15 million Series C financing round. New investors, led by CDP...

at 03:05
Enesi Pharma ("Enesi"), an innovative biotechnology company developing next-generation vaccination products targeting infectious diseases and emergent threat pathogens enabled by its ImplaVax® technologies, is delighted to announce that ImplaVax® has...

at 03:05
Warriors Heart's private residential treatment program for "warriors" announces the purchase of the Bandera Lodge as part of their expansion and continued commitment to healing our frontline protectors. This newly acquired property will become the...

News published on 5 august 2020 at 12:10 and distributed by: